These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 17029278

  • 1. Botulinum toxin and neuromotor rehabilitation: An integrated approach to idiopathic cervical dystonia.
    Tassorelli C, Mancini F, Balloni L, Pacchetti C, Sandrini G, Nappi G, Martignoni E.
    Mov Disord; 2006 Dec; 21(12):2240-3. PubMed ID: 17029278
    [Abstract] [Full Text] [Related]

  • 2. Factors affecting the health-related quality of life of patients with cervical dystonia and the impact of botulinum toxin type A injections.
    Slawek J, Friedman A, Potulska A, Krystkowiak P, Gervais C, Banach M, Ochudlo S, Budrewicz S, Reclawowicz D, Rynkowski M, Opala G.
    Funct Neurol; 2007 Dec; 22(2):95-100. PubMed ID: 17637212
    [Abstract] [Full Text] [Related]

  • 3. Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A.
    Brashear A, Ambrosius WT, Eckert GJ, Siemers ER.
    Mov Disord; 1998 Jan; 13(1):158-61. PubMed ID: 9452343
    [Abstract] [Full Text] [Related]

  • 4. Fast voluntary neck movements in patients with cervical dystonia: a kinematic study before and after therapy with botulinum toxin type A.
    Gregori B, Agostino R, Bologna M, Dinapoli L, Colosimo C, Accornero N, Berardelli A.
    Clin Neurophysiol; 2008 Feb; 119(2):273-80. PubMed ID: 18063411
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study.
    Truong D, Duane DD, Jankovic J, Singer C, Seeberger LC, Comella CL, Lew MF, Rodnitzky RL, Danisi FO, Sutton JP, Charles PD, Hauser RA, Sheean GL.
    Mov Disord; 2005 Jul; 20(7):783-91. PubMed ID: 15736159
    [Abstract] [Full Text] [Related]

  • 6. BotB (botulinum toxin type B): evaluation of safety and tolerability in botulinum toxin type A-resistant cervical dystonia patients (preliminary study).
    Truong DD, Cullis PA, O'Brien CF, Koller M, Villegas TP, Wallace JD.
    Mov Disord; 1997 Sep; 12(5):772-5. PubMed ID: 9380065
    [Abstract] [Full Text] [Related]

  • 7. A prospective, randomized, double-blind study comparing the efficacy and safety of type a botulinum toxins botox and prosigne in the treatment of cervical dystonia.
    Quagliato EM, Carelli EF, Viana MA.
    Clin Neuropharmacol; 2010 Sep; 33(1):22-6. PubMed ID: 19959960
    [Abstract] [Full Text] [Related]

  • 8. Functional outcomes of intramuscular botulinum toxin type a and occupational therapy in the upper limbs of children with cerebral palsy: a randomized controlled trial.
    Wallen M, O'Flaherty SJ, Waugh MC.
    Arch Phys Med Rehabil; 2007 Jan; 88(1):1-10. PubMed ID: 17207668
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Clinical changes of cervical dystonia pattern in long-term botulinum toxin treated patients.
    Maia FM, Kanashiro AK, Chien HF, Gonçalves LR, Barbosa ER.
    Parkinsonism Relat Disord; 2010 Jan; 16(1):8-11. PubMed ID: 19589716
    [Abstract] [Full Text] [Related]

  • 11. Change in lateralization of the P22/N30 cortical component of median nerve somatosensory evoked potentials in patients with cervical dystonia after successful treatment with botulinum toxin A.
    Kanovský P, Streitová H, Dufek J, Znojil V, Daniel P, Rektor I.
    Mov Disord; 1998 Jan; 13(1):108-17. PubMed ID: 9452335
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections.
    Sankhla C, Jankovic J, Duane D.
    Mov Disord; 1998 Jan; 13(1):150-4. PubMed ID: 9452341
    [Abstract] [Full Text] [Related]

  • 14. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R, Schreiber C.
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Improvement in quality of life after botulinum toxin-A injections for idiopathic detrusor overactivity: results from a randomized double-blind placebo-controlled trial.
    Sahai A, Dowson C, Khan MS, Dasgupta P.
    BJU Int; 2009 Jun; 103(11):1509-15. PubMed ID: 19389019
    [Abstract] [Full Text] [Related]

  • 17. Long-term follow-up of cervical dystonia patients treated with botulinum toxin A.
    Haussermann P, Marczoch S, Klinger C, Landgrebe M, Conrad B, Ceballos-Baumann A.
    Mov Disord; 2004 Mar; 19(3):303-8. PubMed ID: 15022184
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The combined effect of lower-limb multilevel botulinum toxin type a and comprehensive rehabilitation on mobility in children with cerebral palsy: a randomized clinical trial.
    Scholtes VA, Dallmeijer AJ, Knol DL, Speth LA, Maathuis CG, Jongerius PH, Becher JG.
    Arch Phys Med Rehabil; 2006 Dec; 87(12):1551-8. PubMed ID: 17141633
    [Abstract] [Full Text] [Related]

  • 20. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm.
    Bihari K.
    Curr Med Res Opin; 2005 Mar; 21(3):433-8. PubMed ID: 15811212
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.